The CC chemokine receptor antagonist Met-RANTES inhibits eosinophil effector functions

International Archives of Allergy and Immunology

Volumn 118, Issue 2-4, 1999, Pages 462-465

  Elsner, Jörn ^a   Petering, Holger ^a   Kimmig, Daniela ^a   Wells, Timothy N C ^b   Proudfoot, Amanda E J ^b   Kapp, Alexander ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

Author keywords

Chemokine antagonist; Chemokines; Eosinophils; Respiratory burst

Indexed keywords

BETA CHEMOKINE; CALCIUM; CELL RECEPTOR; CHEMOKINE; CHEMOKINE RECEPTOR; EOTAXIN; MET RANTES; MONOCYTE CHEMOTACTIC PROTEIN 3; RANTES; REACTIVE OXYGEN METABOLITE; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ALLERGIC ASTHMA; ALLERGIC DISEASE; ATOPIC DERMATITIS; CALCIUM TRANSPORT; CELL ACTIVATION; COMPETITIVE INHIBITION; CONFERENCE PAPER; EOSINOPHIL; HUMAN; HUMAN CELL; INFLAMMATION; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; RHINOCONJUNCTIVITIS; STIMULATION; TISSUE INJURY;

EID: 0032914384     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000024164     Document Type: Conference Paper

References (31)

1. Kapp A: Atopic dermatitis - The skin manifestation of atopy. Clin Exp Allergy 1995;25: 210-219.
2. Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: Biology and role in disease. Adv Immunol 1995;60:151-266.
3. Aractingi S, Janin A, Zini JM, Gauthier MS, Chauvenet L, Tobelem G, Prin L, Chosidow O, Frances C: Specific mucosal erosions in hypereosinophilic syndrome: Evidence for eosinophil protein deposition. Arch Dermatol 1996; 132:535-541.
4. Czech W, Schaller J, Schöpf E, Kapp A: Granulocyte activation in bullous diseases - Release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 1993;29:210-215.
5. Dhami D, Shutte JK: Mechanisms of epithelial damage: Are there parallels between bullous skin diseases and asthma? Clin Exp Allergy 1994;24:1005.
6. Grewe M, Bruijnzeel-Koomen CAFM, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359-361.
7. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, Hanau D, de la Salle C: Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1993;175: 1285-1290.
8. Gleich GJ, Adolphoson CR, Leifermann KM: The biology of the eosinophilic leukocyte. Annu Rev Med 1993;44:85-101.
9. Busse WW, Sedgwick JB: Eosinophils in asthma. Ann Allergy 1992;286:286-290.
10. Rochester CL, Ackermann SJ, Zheng T, Elias JA: Eosinophil-fibroblast interactions - Granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. J Immunol 1996;156:4449-4456.
11. Schröder JM, Noso N, Sticherling M, Christophers E: Role of eosinophil-chemotactic C-C chemokines in cutaneous inflammation. J Leukoc Biol 1996;59:1-5.
12. Coyle AJ, Ackermann S, Burch R, Proud D, Irvin CG: Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest 1995; 95:1735-1740.
13. Ying S, Taborda Barata L, Meng Q, Humbert M, Kay AB: The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: Relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181:2153-2159.
14. Elsner J, Dichmann S, Kapp A: Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. J Invest Dermatol 1995;105:231-236.
15. Kapp A: The role of eosinophils in the pathogenesis of atopic dermatitis - Eosinophil granule proteins as markers of disease activity. Allergy 1993;48:1-5.
16. Elsner J, Hochstetter R, Spiekermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88:4684-4693.
17. Elsner J, Oppermann M, Kapp A: Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies. Eur J Immunol 1996;26:1560-1564.
18. Elsner J, Oppermann M, Czech W, Kapp A: C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 1994;83:3324-3331.
19. Elsner J, Oppermann M, Czech W, Dobos G, Schöpf E, Norgauer J, Kapp A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518-522.
20. Zeck Kapp G, Kroegel C, Riede UN, Kapp A: Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: Similar functional responses are accompanied by different morphologic alterations. Allergy 1995;50:34-47.
21. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998;392:565-568.
22. Moser B, Loetscher M, Piali L, Loetscher P: Lymphocyte responses to chemokines. Int Rev Immunol 1998;16:323-344.
23. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-445.
24. Kapp A, Zeck Kapp G, Czech W, Schöpf E: The chemokine RANTES is more than a chemoattractant: Characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J Invest Dermatol 1994;102: 906-914.
25. Elsner J, Hochstetter R, Kimmig D, Kapp A: Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 1996;26:1919-1925.
26. Petering H, Hochstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J: Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol 1998;160:555-558.
27. Elsner J, Petering H, Kluthe C, Kimmig D, Smolarski R, Ponath P, Kapp A: Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils. Eur J Immunol 1998;28:2152-2158.
28. Gong JH, Clark-Lewis I: Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995;181:631-640.
29. Weber M, Uguccioni M, Baggiolini M, Clark Lewis I, Dahinden CA: Deletion of the NH2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil chemoattractant. J Exp Med 1996;183:681-685.
30. Wells TNC, Power CA, Lusti-Narasimhan M, Hoogewerf AJ, Cooke RM, Chung C, Peitsch MC, Proudfoot AEI: Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996;59:53-60.
31. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599-2603.